{"id":"F2005L04243","name":"National Health (Pharmaceutical Benefits - early supply) Instrument 2005","slug":"national-health-pharmaceutical-benefits-early-supply-instrument-2005","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":40432,"registerId":"commonwealth-F2005L04243-current","compilationNumber":null,"startDate":"2026-04-01","status":"Repealed","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"National Health (Pharmaceutical Benefits - early supply) Instrument 2005","content":"![](image.001.png)\n\nNational Health (Pharmaceutical Benefits — early supply) Instrument 2005\n\nI, TONY ABBOTT, Minister for Health and Ageing, make this Instrument under subsection 84AAA (2) of the National Health Act 1953.\n\nDated 20 December 2005\n\nSigned Tony Abbott\n\nMinister for Health and Ageing\n\n1 Name of Instrument\n\nThis Instrument is the National Health (Pharmaceutical Benefits — early supply) Instrument 2005.\n\n2 Commencement\n\nThis Instrument commences on 1 January 2006.\n\n3 Definitions\n\nIn this Instrument:\n\n> I.M. means intramuscular.\n\n> I.U. means international unit.\n\n> I.V. means intravenous.\n\n4 Pharmaceutical benefits\n\nA pharmaceutical benefit mentioned in Schedule 1 is specified for the purposes of paragraph 84AAA (1) (b) of the National Health Act 1953.\n\nSchedule 1 Pharmaceutical benefits\n\n(section 4)\n\nDo not delete : Schedule Part Placeholder\n\n| Item | Pharmaceutical benefit | Form and strength | Maximum quantity | Maximum number of repeats |\n| ---- | ----------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------- | ------------------------- |\n| 1 | Aciclovir | Tablet 200 mg | 90 | 5 |\n| 2 | Adalimumab | Injection 40 mg in 0.8 mL pre‑filled syringe | 2 | 5 |\n| 3 | Alendronate Sodium | Tablet equivalent to 70 mg alendronic acid | 4 | 5 |\n| | | Tablet equivalent to 40 mg alendronic acid | 30 | 5 |\n| 4 | Amantadine Hydrochloride | Capsule 100 mg | 100 | 5 |\n| 5 | Amlodipine Besylate | Tablet equivalent to 5 mg amlodipine | 30 | 5 |\n| | | Tablet equivalent to 10 mg amlodipine | 30 | 5 |\n| 6 | Anakinra | Injection 100 mg in 0.67 mL single use pre-filled syringe | 28 | 5 |\n| 7 | Anastrazole | Tablet 1 mg | 30 | 5 |\n| 8 | Atenolol | Tablet 50 mg | 30 | 5 |\n| 9 | Atorvastatin Calcium | Tablet equivalent to 10 mg atorvastatin | 30 | 5 |\n| | | Tablet equivalent to 20 mg atorvastatin | 30 | 5 |\n| | | Tablet equivalent to 40 mg atorvastatin | 30 | 5 |\n| | | Tablet equivalent to 80 mg atorvastatin | 30 | 5 |\n| 10 | Auranofin | Tablet 3 mg | 60 | 5 |\n| 11 | Baclofen | Tablet 10 mg | 100 | 5 |\n| | | Tablet 25 mg | 100 | 5 |\n| 12 | Balsalazide Sodium | Capsule 750 mg | 180 | 5 |\n| 13 | Bicalutamide | Tablet 50 mg | 28 | 5 |\n| 14 | Bisoprolol Fumarate | Tablet 2.5 mg | 28 | 5 |\n| | | Tablet 5 mg | 28 | 5 |\n| | | Tablet 10 mg | 28 | 5 |\n| 15 | Cabergoline | Tablet 1 mg | 30 | 5 |\n| | | Tablet 2 mg | 30 | 5 |\n| | | Tablet 4 mg | 30 | 5 |\n| 16 | Candesartan Cilexetil | Tablet 4 mg | 30 | 5 |\n| | | Tablet 8 mg | 30 | 5 |\n| | | Tablet 16 mg | 30 | 5 |\n| 17 | Candesartan Cilexetil with Hydrochlorothiazide | Tablet 16 mg-12.5 mg | 30 | 5 |\n| 18 | Captopril | Tablet 12.5 mg | 90 | 5 |\n| | | Tablet 25 mg | 90 | 5 |\n| | | Tablet 50 mg | 90 | 5 |\n| 19 | Carvedilol | Tablet 6.25 mg | 60 | 5 |\n| | | Tablet 12.5 mg | 60 | 5 |\n| | | Tablet 25 mg | 60 | 5 |\n| 20 | Cimetidine | Tablet 200 mg | 120 | 5 |\n| | | Tablet 400 mg | 60 | 5 |\n| | | Tablet 800 mg | 30 | 5 |\n| 21 | Cimetidine Hydrochloride | Tablet, effervescent, equivalent to 800 mg cimetidine | 30 | 5 |\n| 22 | Clonidine Hydrochloride | Tablet 100 micrograms | 100 | 5 |\n| | | Tablet 150 micrograms | 100 | 5 |\n| 23 | Clopidogrel Hydrogen Sulfate | Tablet equivalent to 75 mg clopidogrel | 28 | 5 |\n| 24 | Diltiazem Hydrochloride | Tablet 60 mg | 90 | 5 |\n| | | Capsule 180 mg (controlled delivery) | 30 | 5 |\n| | | Capsule 240 mg (controlled delivery) | 30 | 5 |\n| | | Capsule 360 mg (controlled delivery) | 30 | 5 |\n| 25 | Dipyridamole | Capsule 200 mg (sustained release) | 60 | 5 |\n| 26 | Dipyridamole with Aspirin | Capsule 200 mg (sustained release)-25 mg | 60 | 5 |\n| 27 | Disodium Etidronate | Tablet 200 mg | 60 | 5 |\n| 28 | Enalapril Maleate | Tablet 5 mg | 30 | 5 |\n| | | Tablet 10 mg | 30 | 5 |\n| | | Tablet 20 mg | 30 | 5 |\n| 29 | Enalapril Maleate with Hydrochlorothiazide | Tablet 20 mg-6 mg | 30 | 5 |\n| 30 | Eprosartan Mesylate | Tablet equivalent to 400 mg eprosartan | 56 | 5 |\n| | | Tablet equivalent to 600 mg eprosartan | 28 | 5 |\n| 31 | Eprosartan Mesylate with Hydrochlorothiazide | Tablet equivalent to 600 mg eprosartan with 12.5 mg hydrochlorothiazide | 28 | 5 |\n| 32 | Esomeprazole Magnesium Trihydrate | Tablet (enteric coated), equivalent to 20 mg esomeprazole | 30 | 5 |\n| 33 | Etanercept | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | 2 | 5 |\n| | | Injection set containing 4 vials powder for injection 50 mg and 4 pre-filled syringes solvent 1 mL | 1 | 5 |\n| 34 | Ezetimibe | Tablet 10 mg | 30 | 5 |\n| 35 | Famciclovir | Tablet 250 mg | 56 | 5 |\n| 36 | Famotidine | Tablet 20 mg | 60 | 5 |\n| | | Tablet 40 mg | 30 | 5 |\n| 37 | Felodipine | Tablet 2.5 mg (extended release) | 30 | 5 |\n| | | Tablet 5 mg (extended release) | 30 | 5 |\n| | | Tablet 10 mg (extended release) | 30 | 5 |\n| 38 | Fenofibrate | Capsule 67 mg | 60 | 5 |\n| | | Tablet 160 mg | 30 | 5 |\n| 39 | Flutamide | Tablet 250 mg | 100 | 5 |\n| 40 | Fluvastatin Sodium | Capsule equivalent to 20 mg fluvastatin | 28 | 5 |\n| | | Capsule equivalent to 40 mg fluvastatin | 28 | 5 |\n| 41 | Fosinopril Sodium | Tablet 10 mg | 30 | 5 |\n| | | Tablet 20 mg | 30 | 5 |\n| 42 | Fosinopril Sodium with Hydrochlorothiazide | Tablet 10 mg-12.5 mg | 30 | 5 |\n| | | Tablet 20 mg-12.5 mg | 30 | 5 |\n| 43 | Gemfibrozil | Tablet 600 mg | 60 | 5 |\n| 44 | Glyceryl Trinitrate | Transdermal patch 18 mg | 30 | 5 |\n| | | Transdermal patch 25 mg | 30 | 5 |\n| | | Transdermal patch 36 mg | 30 | 5 |\n| | | Transdermal patch 40 mg | 30 | 5 |\n| | | Transdermal patch 50 mg | 30 | 5 |\n| | | Transdermal patch 54 mg | 30 | 5 |\n| | | Transdermal patch 80 mg | 30 | 5 |\n| | | Transdermal patch 120 mg | 30 | 5 |\n| 45 | Irbesartan | Tablet 75 mg | 30 | 5 |\n| | | Tablet 150 mg | 30 | 5 |\n| | | Tablet 300 mg | 30 | 5 |\n| 46 | Irbesartan with Hydrochlorothiazide | Tablet 150 mg-12.5 mg | 30 | 5 |\n| | | Tablet 300 mg-12.5 mg | 30 | 5 |\n| 47 | Isosorbide Mononitrate | Tablet 60 mg (sustained release) | 30 | 5 |\n| | | Tablet 120 mg (sustained release) | 30 | 5 |\n| 48 | Labetalol Hydrochloride | Tablet 100 mg | 100 | 5 |\n| | | Tablet 200 mg | 100 | 5 |\n| 49 | Lansoprazole | Capsule 15 mg | 30 | 5 |\n| | | Capsule 30 mg | 30 | 5 |\n| | | Sachet containing granules for oral suspension, 30 mg per sachet | 28 | 5 |\n| 50 | Leflunomide | Tablet 10 mg | 30 | 5 |\n| | | Tablet 20 mg | 30 | 5 |\n| 51 | Lercanidipine Hydrochloride | Tablet 10 mg | 30 | 5 |\n| | | Tablet 20 mg | 30 | 5 |\n| 52 | Lisinopril | Tablet 5 mg | 30 | 5 |\n| | | Tablet 10 mg | 30 | 5 |\n| | | Tablet 20 mg | 30 | 5 |\n| 53 | Mesalazine | Tablet 250 mg | 100 | 5 |\n| | | Tablet 500 mg (enteric coated) | 100 | 5 |\n| | | Sachet containing granules, 500 mg per sachet | 100 | 5 |\n| 54 | Methyldopa | Tablet 250 mg | 100 | 5 |\n| 55 | Metoprolol Succinate | Tablet 47.5 mg (controlled release) | 30 | 5 |\n| | | Tablet 95 mg (controlled release) | 30 | 5 |\n| | | Tablet 190 mg (controlled release) | 30 | 5 |\n| 56 | Metoprolol Tartrate | Tablet 50 mg | 100 | 5 |\n| | | Tablet 100 mg | 60 | 5 |\n| 57 | Minocycline Hydrochloride | Tablet equivalent to 50 mg minocycline | 60 | 5 |\n| 58 | Minoxidil | Tablet 10 mg | 100 | 5 |\n| 59 | Modafinil | Tablet 100 mg | 120 | 5 |\n| 60 | Nicorandil | Tablets 10 mg, 60 | 1 | 5 |\n| | | Tablets 20 mg, 60 | 1 | 5 |\n| 61 | Nifedipine | Tablet 10 mg | 60 | 5 |\n| | | Tablet 20 mg | 60 | 5 |\n| | | Tablet 20 mg (controlled release) | 30 | 5 |\n| | | Tablet 30 mg (controlled release) | 30 | 5 |\n| | | Tablet 60 mg (controlled release) | 30 | 5 |\n| 62 | Nilutamide | Tablet 150 mg | 30 | 5 |\n| 63 | Nizatidine | Capsule 150 mg | 60 | 5 |\n| | | Capsule 300 mg | 30 | 5 |\n| 64 | Oestradiol | Transdermal patches 390 micrograms, 8 | 1 | 5 |\n| | | Transdermal patches 2 mg, 4 | 1 | 5 |\n| | | Transdermal patches 2 mg, 8 (Dermestril 25) | 1 | 5 |\n| | | Transdermal patches 2 mg, 8 (Estraderm 25) | 1 | 5 |\n| | | Transdermal patches 585 micrograms, 8 | 1 | 5 |\n| | | Transdermal patches 3.28 mg, 8 | 1 | 5 |\n| | | Transdermal patches 780 micrograms, 8 | 1 | 5 |\n| | | Transdermal patches 3.8 mg, 4 | 1 | 5 |\n| | | Transdermal patches 4 mg, 8 (Dermestril 50) | 1 | 5 |\n| | | Transdermal patches 4 mg, 8 (Estraderm 50) | 1 | 5 |\n| | | Transdermal patches 4.33 mg, 8 | 1 | 5 |\n| | | Transdermal patches 1.17 mg, 8 | 1 | 5 |\n| | | Transdermal patches 5.7 mg, 4 | 1 | 5 |\n| | | Transdermal patches 6.57 mg, 8 | 1 | 5 |\n| | | Transdermal patches 1.56 mg, 8 | 1 | 5 |\n| | | Transdermal patches 7.6 mg, 4 | 1 | 5 |\n| | | Transdermal patches 8 mg, 8 (Dermestril 100) | 1 | 5 |\n| | | Transdermal patches 8 mg, 8 (Estraderm 100) | 1 | 5 |\n| | | Transdermal patches 8.66 mg, 8 | 1 | 5 |\n| 65 | Oestradiol and Oestradiol with Dydrogesterone | Pack containing 14 tablets oestradiol 2 mg and 14 tablets oestradiol 2 mg with dydrogesterone 10 mg | 1 | 5 |\n| 66 | Oestradiol and Oestradiol with Norethisterone Acetate | Pack containing 12 tablets oestradiol 2 mg, 10 tablets oestradiol 2 mg with norethisterone acetate 1 mg and 6 tablets oestradiol 1 mg | 1 | 5 |\n| | | Pack containing 4 transdermal patches oestradiol 4 mg and 4 transdermal patches oestradiol 10 mg with norethisterone acetate 30 mg | 1 | 5 |\n| 67 | Oestradiol Hemihydrate | Nasal spray 150 micrograms per actuation, 60 actuations, 4.2 mL | 1 | 5 |\n| | | Transdermal gel equivalent to 1 mg oestradiol in 1 g sachet, 28 | 1 | 5 |\n| | | Transdermal patches equivalent to 750 micrograms oestradiol, 8 | 1 | 5 |\n| | | Transdermal patches equivalent to 1.5 mg oestradiol, 8 | 1 | 5 |\n| | | Transdermal patches equivalent to 3 mg oestradiol, 8 | 1 | 5 |\n| 68 | Oestradiol Hemihydrate and Oestradiol Hemihydrate with Norethisterone Acetate | Pack containing 4 transdermal patches equivalent to 4.33 mg oestradiol and 4 transdermal patches equivalent to 620 micrograms oestradiol with 2.7 mg norethisterone acetate | 1 | 5 |\n| | | Pack containing 4 transdermal patches equivalent to 4.33 mg oestradiol and 4 transdermal patches equivalent to 510 micrograms oestradiol with 4.8 mg norethisterone acetate | 1 | 5 |\n| 69 | Oestradiol Hemihydrate with Norethisterone Acetate | Tablets equivalent to 1 mg oestradiol with 500 micrograms norethisterone acetate, 28 | 1 | 5 |\n| | | Tablets equivalent to 2 mg oestradiol with 1 mg norethisterone acetate, 28 | 1 | 5 |\n| | | Transdermal patches equivalent to 620 micrograms oestradiol with 2.7 mg norethisterone acetate, 8 | 1 | 5 |\n| | | Transdermal patches equivalent to 510 micrograms oestradiol with 4.8 mg norethisterone acetate, 8 | 1 | 5 |\n| 70 | Oestradiol Valerate and Oestradiol Valerate with Cyproterone Acetate | Pack containing 11 tablets oestradiol valerate 2 mg and 10 tablets oestradiol valerate 2 mg with cyproterone acetate 1 mg | 1 | 5 |\n| 71 | Oestrogens—Conjugated with Medroxyprogesterone Acetate | Tablets 625 micrograms-2.5 mg, 28 | 1 | 5 |\n| | | Tablets 625 micrograms-5 mg, 28 | 1 | 5 |\n| 72 | Olsalazine Sodium | Capsule 250 mg | 100 | 5 |\n| | | Tablet 500 mg | 100 | 5 |\n| 73 | Omeprazole | Tablet 20 mg | 30 | 5 |\n| | | Tablet 10 mg | 30 | 5 |\n| | | Capsule 20 mg | 30 | 5 |\n| 74 | Oxprenolol Hydrochloride | Tablet 20 mg | 100 | 5 |\n| | | Tablet 40 mg | 100 | 5 |\n| 75 | Pantoprazole Sodium Sesquihydrate | Tablet (enteric coated), equivalent to 40 mg pantoprazole | 30 | 5 |\n| | | Tablet (enteric coated), equivalent to 20 mg pantoprazole | 30 | 5 |\n| 76 | Pergolide Mesylate | Tablet equivalent to 250 micrograms pergolide | 100 | 5 |\n| | | Tablet equivalent to 1 mg pergolide | 100 | 5 |\n| 77 | Perhexiline Maleate | Tablet 100 mg | 100 | 5 |\n| 78 | Perindopril Erbumine | Tablet 2 mg | 30 | 5 |\n| | | Tablet 4 mg | 30 | 5 |\n| | | Tablet 8 mg | 30 | 5 |\n| 79 | Perindopril Erbumine with Indapamide Hemihydrate | Tablet 4 mg-1.25 mg | 30 | 5 |\n| 80 | Phenoxybenzamine Hydrochloride | Capsule 10 mg | 100 | 5 |\n| 81 | Pindolol | Tablet 5 mg | 100 | 5 |\n| | | Tablet 15 mg | 50 | 5 |\n| 82 | Pravastatin Sodium | Tablet 10 mg | 30 | 5 |\n| | | Tablet 20 mg | 30 | 5 |\n| | | Tablet 40 mg | 30 | 5 |\n| | | Tablet 80 mg | 30 | 5 |\n| 83 | Prazosin Hydrochloride | Tablet equivalent to 1 mg prazosin | 100 | 5 |\n| | | Tablet equivalent to 2 mg prazosin | 100 | 5 |\n| | | Tablet equivalent to 5 mg prazosin | 100 | 5 |\n| 84 | Probenecid | Tablet 500 mg | 100 | 5 |\n| 85 | Propranolol Hydrochloride | Tablet 10 mg | 100 | 5 |\n| | | Tablet 40 mg | 100 | 5 |\n| | | Tablet 160 mg | 50 | 5 |\n| 86 | Quinapril Hydrochloride | Tablet equivalent to 5 mg quinapril | 30 | 5 |\n| | | Tablet equivalent to 10 mg quinapril | 30 | 5 |\n| | | Tablet equivalent to 20 mg quinapril | 30 | 5 |\n| 87 | Quinapril Hydrochloride with Hydrochlorothiazide | Tablet equivalent to 10 mg quinapril with 12.5 mg hydrochlorothiazide | 30 | 5 |\n| | | Tablet equivalent to 20 mg quinapril with 12.5 mg hydrochlorothiazide | 30 | 5 |\n| 88 | Rabeprazole Sodium | Tablet 10 mg (enteric coated) | 28 | 5 |\n| | | Tablet 20 mg (enteric coated) | 30 | 5 |\n| 89 | Raloxifene Hydrochloride | Tablet 60 mg | 28 | 5 |\n| 90 | Ramipril | Tablet 1.25 mg | 30 | 5 |\n| | | Tablet 2.5 mg | 30 | 5 |\n| | | Tablet 5 mg | 30 | 5 |\n| | | Capsule 10 mg | 30 | 5 |\n| 91 | Ranitidine Hydrochloride | Tablet equivalent to 150 mg ranitidine | 60 | 5 |\n| | | Tablet, effervescent, equivalent to 150 mg ranitidine | 60 | 5 |\n| | | Tablet equivalent to 300 mg ranitidine | 30 | 5 |\n| | | Syrup equivalent to 150 mg ranitidine per 10 mL, 300 mL | 2 | 5 |\n| 92 | Riluzole | Tablet 50 mg | 56 | 5 |\n| 93 | Risedronate Sodium | Tablet 5 mg | 28 | 5 |\n| | | Tablet 35 mg | 4 | 5 |\n| 94 | Salcatonin | Injection 50 I.U. in 1 mL ampoule | 30 | 5 |\n| | | Injection 100 I.U. in 1 mL ampoule | 15 | 5 |\n| 95 | Selegiline Hydrochloride | Tablet 5 mg | 100 | 5 |\n| 96 | Simvastatin | Tablet 5 mg | 30 | 5 |\n| | | Tablet 10 mg | 30 | 5 |\n| | | Tablet 20 mg | 30 | 5 |\n| | | Tablet 40 mg | 30 | 5 |\n| | | Tablet 80 mg | 30 | 5 |\n| 97 | Spironolactone | Tablet 25 mg | 100 | 5 |\n| | | Tablet 100 mg | 100 | 5 |\n| 98 | Sulfasalazine | Tablet 500 mg | 200 | 5 |\n| | | Tablet 500 mg (enteric coated) | 200 | 5 |\n| 99 | Tamoxifen Citrate | Tablet equivalent to 10 mg tamoxifen | 60 | 5 |\n| | | Tablet equivalent to 20 mg tamoxifen | 60 | 5 |\n| 100 | Telmisartan | Tablet 40 mg | 28 | 5 |\n| | | Tablet 80 mg | 28 | 5 |\n| 101 | Telmisartan with Hydrochlorothiazide | Tablet 40 mg-12.5 mg | 28 | 5 |\n| | | Tablet 80 mg-12.5 mg | 28 | 5 |\n| 102 | Testosterone | Transdermal gel 50 mg in 5 g sachet, 30 | 1 | 5 |\n| | | Transdermal patches 12.2 mg, 60 | 1 | 5 |\n| | | Transdermal patches 24.3 mg, 30 | 1 | 5 |\n| 103 | Testosterone Undecanoate | Capsule 40 mg | 60 | 5 |\n| 104 | Theophylline | Tablet 200 mg (sustained release) | 100 | 5 |\n| | | Tablet 250 mg (sustained release) | 100 | 5 |\n| | | Tablet 300 mg (sustained release) | 100 | 5 |\n| 105 | Ticlopidine Hydrochloride | Tablet 250 mg | 60 | 5 |\n| 106 | Tiotropium Bromide Monohydrate | Capsule containing powder for oral inhalation equivalent to 18 micrograms tiotropium (for use in HandiHaler) | 30 | 5 |\n| 107 | Trandolapril | Capsule 500 micrograms | 28 | 5 |\n| | | Capsule 1 mg | 28 | 5 |\n| | | Capsule 2 mg | 28 | 5 |\n| | | Capsule 4 mg | 28 | 5 |\n| 108 | Valaciclovir Hydrochloride | Tablet equivalent to 500 mg valaciclovir | 30 | 5 |\n| 109 | Verapamil Hydrochloride | Tablet 40 mg | 100 | 5 |\n| | | Tablet 80 mg | 100 | 5 |\n| | | Tablet 120 mg | 100 | 5 |\n| | | Tablet 160 mg | 60 | 5 |\n| | | Tablet 180 mg (sustained release) | 30 | 5 |\n| | | Tablet 240 mg (sustained release) | 30 | 5 |\n| | | Capsule 160 mg (sustained release) | 30 | 5 |\n| | | Capsule 240 mg (sustained release) | 30 | 5 |","sortOrder":0}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-realtime","completionTokens":1685},"content_quality":"ok","complexity_score":2,"rejection_reason":"","scope_assessment":{"changed":false,"description":"This instrument maintains its original 2005 scope. It operates as a straightforward specification of pharmaceutical benefits for early supply purposes under section 84AAA of the National Health Act 1953, exactly as indicated by its title and enabling provision. The content consists entirely of the medication schedule without expansion into procedural or eligibility rules."},"complexity_factors":["Extensive tabular schedule containing 109 distinct pharmaceutical items","Multiple formulation variants per item (different strengths, delivery methods, and packaging)","Technical medical terminology requiring pharmaceutical knowledge to interpret (e.g., 'enteric coated', 'controlled delivery', 'I.M.', 'I.U.')","Single cross-reference to enabling legislation (National Health Act 1953) without explanatory context for section 84AAA"],"plain_english_summary":"This instrument establishes a defined list of 109 PBS medicines that pharmacists may supply early (e.g., for travellers or lost meds), setting legal permission to dispense before normal refill intervals. \n\nIt specifies eligible products by form/strength and caps on early quantity and repeats, affecting patients who need uninterrupted treatment, pharmacists making supply decisions, and prescribers. The list gives clarity and reduces risk of patients running out of essential medicines."},"flash_summary":{"complexity_score":4,"scope_assessment":{"changed":false,"description":"The Instrument itself simply designates the Schedule 1 items as pharmaceutical benefits for the purposes of paragraph 84AAA(1)(b) of the National Health Act 1953 and sets a commencement date (section 4; section 2). It does not state any amendment, removal or broader expansion of statutory scope within the text, so no scope change is evident from the instrument alone."},"complexity_factors":["Long, detailed schedule: 109 listed items with multiple strengths, forms, pack sizes, maximum quantities and repeat limits creates operational complexity for dispensers to match prescriptions exactly (Schedule 1).","Legal cross‑references: instrument is made under subsection 84AAA(2) and specifies benefits for paragraph 84AAA(1)(b) of the National Health Act 1953 — legal effect depends on interpreting that external provision (preamble; section 4).","Limited definitions: only I.M., I.U., I.V. are defined in the instrument, so other clinical terms must be interpreted against usual clinical/pharmaceutical practice, increasing reliance on professional judgment (section 3).","Commencement timing: fixed commencement date requires administrative preparedness by 1 January 2006 (section 2).","Compliance requirements: each Schedule entry specifies a maximum quantity and maximum number of repeats, creating clear but numerous compliance checks for pharmacies and prescribers (Schedule 1).","Absence of payment mechanics: the instrument does not describe who pays or how PBS subsidies are administered; financial consequences therefore depend on the National Health Act/PBS framework outside this text (section 4).","Potential ambiguity across multiple entries: medicines appearing in several forms or strengths (eg. tablets, patches, injections) may raise matching issues for dispensing and claims processing (Schedule 1).","Decision‑making concentration: the instrument was made by the Minister under statutory power, centralising the choice of which items are specified without detailing further administrative delegation or criteria (preamble)."],"plain_english_summary":"This Instrument names specific medicines, strengths, pack sizes, maximum quantities and permitted repeats (in Schedule 1) that are to be treated as pharmaceutical benefits for the early‑supply rule in paragraph 84AAA(1)(b) of the National Health Act 1953. It takes effect 1 January 2006 and affects patients, prescribers and pharmacies by defining which products may be supplied under the Act’s early‑supply arrangement."}},"importantCases":[],"_links":{"self":"/api/acts/national-health-pharmaceutical-benefits-early-supply-instrument-2005","history":"/api/acts/national-health-pharmaceutical-benefits-early-supply-instrument-2005/history","analysis":"/api/acts/national-health-pharmaceutical-benefits-early-supply-instrument-2005/analysis","conflicts":"/api/acts/national-health-pharmaceutical-benefits-early-supply-instrument-2005/conflicts","importantCases":"/api/acts/national-health-pharmaceutical-benefits-early-supply-instrument-2005/important-cases","documents":"/api/acts/national-health-pharmaceutical-benefits-early-supply-instrument-2005/documents"}}